Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis.
OBJECTIVE
We determine the prevalence and patterns of the use of complementary therapies among patients with and those at high risk for prostate cancer.


METHODS
A cross-sectional survey was performed of men presenting to 2 urban tertiary urology clinics for prostate cancer evaluation or followup, and those attending a prostate cancer support group. All men diagnosed with and those at high risk (positive family history or abnormal prostate specific antigen) for prostate cancer were eligible for study. A 9-item self-administered, anonymous questionnaire about complementary therapies was administered.


RESULTS
Of 357 patients who received the survey 155 from the urology clinics and 113 from the support group responded, for a total response rate of 75%. Of the patients presenting to urology clinics and the support group 27.4 and 38.9% with and 25.8 and 80% at high risk for prostate cancer, respectively, used some form of complementary therapy. The use significantly differed according to disease status (p = 0.001), and was highest among men who were clinically disease-free after radical therapy. Of the patients 24% did not inform the urologist of using alternative therapy.


CONCLUSIONS
The prevalence of the use of complementary therapy among patients with or at increased risk for prostate cancer was high and dependent on the disease state. Urologists should be aware of this pattern of use, and consider the potential effects when assessing patients for and with prostate cancer.
Nam
R K
RK
Division of Urology, Sunnybrook Health Science Centre and The Toronto Hospital, University of Toronto, Ontario, Canada.
Fleshner
N
N
Rakovitch
E
E
Klotz
L
L
Trachtenberg
J
J
Choo
R
R
Morton
G
G
Danjoux
C
C
D000368:Aged; D000369:Aged, 80 and over; D000529:Complementary Therapies / Q000706:statistics & numerical data*; D003430:Cross-Sectional Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011471:Prostatic Neoplasms / Q000628:therapy*; D012307:Risk Factors; D011795:Surveys and Questionnaires